Publication:
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Placeholder

Organizational Units

Program

Authors

Authors

TÜRK, HACI MEHMET
Tsuboi M.
Herbst R. S.
John T.
Kato T.
Majem M.
Grohé C.
Wang J.
Goldman J. W.
Lu S.

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source:

Keywords:

Keywords

Citation

Tsuboi M., Herbst R. S., John T., Kato T., Majem M., Grohé C., Wang J., Goldman J. W., Lu S., Su W., et al., "Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.", The New England journal of medicine, cilt.389, sa.2, ss.137-147, 2023

Endorsement

Review

Supplemented By

Referenced By

1

Views

0

Downloads

View PlumX Details


Sustainable Development Goals